Table 1.
Novel breast cancer risk loci identified by cross-ancestry meta-analysis of African and European populations.
| African-specific meta-analysis | European-specific meta-analysis | Combined African and European meta-analysisa | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Chr | Position | Test | Other | Locus | Within gene | TAF | OR (95% CI) | P value | TAF | OR (95% CI) | P value | TAF | OR (95% CI) | P value |
| Overall | |||||||||||||||
| rs17024629 | 1 | 110,179,756 | T | C | 1p13.3 | No | 0.13 | 0.88 (0.83–0.95) | 5.2E−04 | 0.16 | 0.96 (0.94–0.98) | 1.2E−06 | 0.16 | 0.95 (0.94–0.97) | 3.0E−08 |
| rs67931591 | 1 | 215,330,292 | G |
GCTGAGG- CAGGAGA |
1q41 | KCNK2 | 0.28 | 0.95 (0.90–1.00) | 0.034 | 0.68 | 0.98 (0.96–0.99) | 3.9E−04 | 0.66 | 0.97 (0.96–0.99) | 7.4E−05 |
| rs2522057 | 5 | 131,801,947 | C | G | 5q31.1 | C5orf56 | 0.86 | 0.92 (0.86–0.98) | 0.0084 | 0.59 | 0.97 (0.96–0.98) | 9.3E−08 | 0.60 | 0.97 (0.95–0.98) | 1.1E−08 |
| rs1637365 | 7 | 74,359,358 | T | C | 7q11.23 | No | 0.62 | 1.06 (1.01–1.12) | 0.024 | 0.28 | 1.04 (1.02–1.05) | 3.3E−06 | 0.31 | 1.04 (1.02–1.05) | 3.6E−07 |
| rs1869959 | 15 | 75,147,332 | A | C | 15q24.1 | SCAMP2 | 0.40 | 0.95 (0.91–1.00) | 0.043 | 0.30 | 0.97 (0.95–0.98) | 3.6E−07 | 0.30 | 0.96 (0.95–0.98) | 4.6E−08 |
| rs60381548 | 15 | 75,728,474 | CA | C | 15q24.2 | SIN3A | 0.50 | 0.93 (0.89–0.97) | 0.0016 | 0.25 | 0.96 (0.95–0.98) | 4.0E−07 | 0.27 | 0.96 (0.95–0.97) | 6.6E−09 |
| rs181337095 | 15 | 100,907,094 | A | G | 15q26.3 | No | 0.69 | 1.06 (1.01–1.12) | 0.017 | 0.87 | 1.05 (1.03–1.07) | 3.4E−07 | 0.84 | 1.05 (1.04–1.07) | 1.8E−08 |
| ER negative | |||||||||||||||
| rs17024629 | 1 | 110,179,756 | T | C | 1p13.3 | No | 0.13 | 0.83 (0.74–0.92) | 0.00064 | 0.16 | 0.96 (0.93–0.99) | 0.020 | 0.16 | 0.95 (0.93–0.98) | 0.0014 |
| rs67931591 | 1 | 215,330,292 | G |
GCTGAGG- CAGGAGA |
1q41 | KCNK2 | 0.29 | 0.92 (0.85–0.99) | 0.024 | 0.68 | 0.94 (0.92–0.96) | 4.6E−07 | 0.65 | 0.94 (0.92–0.96) | 4.3E−08 |
| rs2522057 | 5 | 131,801,947 | C | G | 5q31.1 | C5orf56 | 0.86 | 0.93 (0.85–1.03) | 0.18 | 0.59 | 0.99 (0.96–1.01) | 0.22 | 0.60 | 0.98 (0.96–1.01) | 0.14 |
| rs1637365 | 7 | 74,359,358 | T | C | 7q11.23 | No | 0.61 | 1.15 (1.06–1.25) | 0.00069 | 0.28 | 1.07 (1.04–1.10) | 9.0E−07 | 0.32 | 1.08 (1.05–1.11) | 1.0E−08 |
| rs1869959 | 15 | 75,147,332 | A | C | 15q24.1 | SCAMP2 | 0.41 | 0.96 (0.89–1.03) | 0.22 | 0.30 | 0.97 (0.94–0.99) | 0.0050 | 0.31 | 0.96 (0.94–0.99) | 0.0022 |
| rs60381548 | 15 | 75,728,474 | CA | C | 15q24.2 | SIN3A | 0.51 | 0.99 (0.92–1.06) | 0.78 | 0.25 | 0.95 (0.92–0.97) | 8.6E−05 | 0.28 | 0.95 (0.93–0.98) | 1.7E−04 |
| rs181337095 | 15 | 100,907,094 | A | G | 15q26.3 | No | 0.69 | 1.07 (0.99–1.16) | 0.067 | 0.87 | 1.06 (1.02–1.10) | 0.0016 | 0.83 | 1.06 (1.03–1.10) | 2.9E−04 |
TAF Test allele frequency, SNP single nucleotide polymorphism, OR odds ratio, CI confidence intervals.
aTest for heterogeneity across studies was statistically significant only for rs1637365 and ER-negative breast cancer (P-for-heterogeneity = 0.025).